Thrive Health Places No. 21 on The Globe and Mail’s Fifth-Annual Ranking of Canada’s Top Growing Companies

Thrive Health is pleased to announce it placed No. 21 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. In total, 425 companies earned a spot on this year’s ranking. Thrive Health, a leader in Canadian healthcare…

Read MoreThrive Health Places No. 21 on The Globe and Mail’s Fifth-Annual Ranking of Canada’s Top Growing Companies

FineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study

FineHeart S.A, a medical device company developing innovative devices for cardiology announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single…

Read MoreFineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region. One of Lokavant’s earliest customers, CMIC Group, is the…

Read MoreLokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more…

Read MoreAbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for sotatercept, Merck’s novel investigational activin…

Read MoreMerck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

United Medical Device Cleaning & Recycling Market Insights, 2022-2023 & 2028 Featuring Key Vendors – Steris, Getinge, ECOLAB, 3M, and Stryker – ResearchAndMarkets.com

The “US Medical Device Cleaning & Recycling Market – Focused Insights 2023-2028” report has been added to ResearchAndMarkets.com’s offering. In the US, the medical device cleaning & recycling market was valued at $3.52 billion in 2022 and is expected to grow at a CAGR…

Read MoreUnited Medical Device Cleaning & Recycling Market Insights, 2022-2023 & 2028 Featuring Key Vendors – Steris, Getinge, ECOLAB, 3M, and Stryker – ResearchAndMarkets.com